- Solid Tumors
- Pipeline Molecules
- Alliance Partners
Our mission is to provide healthcare professionals with unbiased clinical research information, easily.
Currently, you can access the following clinical trials being conducted worldwide:
ADC molecules are engineered to deliver potent cytotoxic compounds to specific antigen-expressing target cells.1,2 Antigen binding domains recognize specific surface proteins, such as B-cell maturation antigen (BCMA), which allows for targeting of cells expressing BCMA, such as plasma and multiple myeloma cells .1,2 ADCs built with non-natural amino acid linkers could potentially ensure that the cytotoxic payload reaches the target cell.1,3 Cytotoxic molecules induce cell death when internalized by antigen-expressing target cells.3 Preclinical studies have shown that ADCs can attack tumors directly, independent of the immune system.4 Preclinical studies are ongoing to optimize, improve, and assess the potential benefits and risks of ADCs as single agent therapy or in combination with other therapies.3,5